Drugs / Quarfloxin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00955292 | Jul 2007 → Apr 2008 | cancer, lymphoma | Cylene Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00955786 | Jul 2005 → Jul 2007 | cancer, lymphoma | Cylene Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00780663 | Oct 2008 → Mar 2010 | carcinoid tumor | Cylene Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quarfloxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00955292 ↗ |
| Known as | CX-3543 | “This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three...” NCT00955292 ↗ |
| Modality | Small molecule | “first-in-class small-molecule targeted cancer therapeutic” NCT00955292 ↗ |
| Route | Intravenous | “IV Quarfloxin 240 mg/m2 daily x5 days every 21 days” NCT00780663 ↗ |